Table 7 summarizes the changes of SBP in hepatic impairments when combination of nifedipine with apatinib. The predicted Rmax and AUE changes of nifedipine in the presence to the absence of apatinib in cancer patients and in hepatic impairments are all within 1.25-fold. Results show that the exposure changes of nifedipine caused by co-administration of apatinib has little effect on the SBP, indicating that apatinib is unlikely to cause severe pharmacodynamic DDI via inhibition of CYP3A4. The gene discussed is CYP3A4; the disease is cancer.